Armistice Capital and Steven Boyd report beneficial ownership of 4,897,417 shares of Travere Therapeutics common stock (5.27%) via a joint Schedule 13G filing. The filing states Armistice Capital acts as investment manager to Armistice Capital Master Fund Ltd., which directly holds the shares, and Mr. Boyd may be deemed to beneficially own them as managing member. The Master Fund disclaims beneficial ownership arising solely from its inability to vote or dispose of the shares under its Investment Management Agreement with Armistice Capital.
Positive
None.
Negative
None.
Insights
Large passive stake disclosed: 4,897,417 shares (5.27%) held through a master fund.
The filing lists 4,897,417 shares and a 5.27% ownership figure as the reported beneficial position. It states Armistice Capital is the investment manager of the Master Fund, which is the direct holder, and that voting and investment power are exercised pursuant to an Investment Management Agreement.
Disclosure is typical for passive/large-holder reporting; subsequent amendments could show changes. Future SEC reports from the reporting persons would reveal any shifts in shared voting or dispositive power.
Joint filing clarifies managerial attribution and disclaimers; ownership is shared voting/dispositive power.
The statement attributes shared voting power and shared dispositive power of 4,897,417 shares to Armistice Capital and Mr. Boyd. It also includes the Master Fund's formal disclaimer regarding direct beneficial ownership due to the management agreement.
This filing documents who may influence votes or sales; any changes to that arrangement would appear in later Schedule 13 filings or amendments.
Key Figures
Beneficially owned shares:4,897,417 sharesPercent of class:5.27%Shared voting power:4,897,417 shares+1 more
4 metrics
Beneficially owned shares4,897,417 sharesamount beneficially owned reported in Schedule 13G
Percent of class5.27%percent of class reported in Schedule 13G
Shared voting power4,897,417 sharesshared voting power reported in Item 4(c)(ii)
Shared dispositive power4,897,417 sharesshared dispositive power reported in Item 4(c)(iv)
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
Investment Management Agreementlegal
"under its Investment Management Agreement with Armistice Capital"
An investment management agreement is a written contract that hires a professional to make buying, selling and strategy decisions for an investment account or fund, and sets out their duties, fees, risk limits, performance measures and reporting requirements. It matters to investors because the agreement determines who controls the money, how much the service costs, what risks are allowed, and how success or failure is measured—think of it as the service contract that defines expectations and remedies for a hired portfolio manager.
beneficial ownershipfinancial
"Amount beneficially owned: 4,897,417"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
What stake did Armistice Capital report in Travere Therapeutics (TVTX)?
Armistice Capital reported beneficial ownership of 4,897,417 shares, or 5.27% of the class. The shares are held directly by Armistice Capital Master Fund Ltd., with Armistice Capital exercising voting and investment power under an Investment Management Agreement.
Does Steven Boyd personally hold the shares reported for TVTX?
Steven Boyd is listed as managing member and may be deemed to beneficially own the shares. The filing states Mr. Boyd may be deemed to beneficially own the Master Fund's holdings because he is managing member of Armistice Capital, the investment manager.
Who directly holds the 4,897,417 Travere shares in the filing?
The direct holder is Armistice Capital Master Fund Ltd. The filing explains the Master Fund is the direct holder and Armistice Capital, as investment manager, exercises voting and investment power under their Investment Management Agreement.
What voting and dispositive powers are reported for the TVTX shares?
The filing reports 0 sole voting/dispositive power and 4,897,417 shared voting/dispositive power. It lists shared power to vote and dispose of the shares, with no sole voting or sole dispositive power claimed in the statement.
Does the Master Fund claim beneficial ownership in the filing?
The Master Fund disclaims beneficial ownership arising from its inability to vote or dispose of the securities under the Investment Management Agreement. The filing still identifies the Master Fund as the direct holder with Armistice Capital exercising voting and investment power.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
TRAVERE THERAPEUTICS, INC.
(Name of Issuer)
Common Stock, par value $0.0001 per share
(Title of Class of Securities)
89422G107
(CUSIP Number)
03/31/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
89422G107
1
Names of Reporting Persons
Armistice Capital, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
4,897,417.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
4,897,417.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
4,897,417.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.27 %
12
Type of Reporting Person (See Instructions)
IA, OO
SCHEDULE 13G
CUSIP Number(s):
89422G107
1
Names of Reporting Persons
Steven Boyd
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
4,897,417.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
4,897,417.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
4,897,417.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.27 %
12
Type of Reporting Person (See Instructions)
HC, IN
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
TRAVERE THERAPEUTICS, INC.
(b)
Address of issuer's principal executive offices:
3611 Valley Centre Drive, Suite 300, San Diego, CA 92130
Item 2.
(a)
Name of person filing:
Armistice Capital, LLC
Steven Boyd
Collectively, the "Reporting Persons"
(b)
Address or principal business office or, if none, residence:
Armistice Capital, LLC
510 Madison Avenue, 7th Floor
New York, New York 10022
United States of America
Steven Boyd
c/o Armistice Capital, LLC
510 Madison Avenue, 7th Floor
New York, New York 10022
United States of America
(c)
Citizenship:
Armistice Capital, LLC - Delaware; Steven Boyd - United States of America
(d)
Title of class of securities:
Common Stock, par value $0.0001 per share
(e)
CUSIP Number(s):
89422G107
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
4,897,417
(b)
Percent of class:
5.27%
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
0
(ii) Shared power to vote or to direct the vote:
4,897,417
(iii) Sole power to dispose or to direct the disposition of:
0
(iv) Shared power to dispose or to direct the disposition of:
4,897,417
Armistice Capital, LLC ("Armistice Capital") is the investment manager of Armistice Capital Master Fund Ltd. (the "Master Fund"), the direct holder of the Shares, and pursuant to an Investment Management Agreement, Armistice Capital exercises voting and investment power over the securities of the Issuer held by the Master Fund and thus may be deemed to beneficially own the securities of the Issuer held by the Master Fund. Mr. Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities of the Issuer held by the Master Fund. The Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital.
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
The Master Fund, a Cayman Islands exempted company that is an investment advisory client of Armistice Capital, has the right to receive dividends from, or the proceeds from the sale of, the reported securities.
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Armistice Capital, LLC
Signature:
/s/ Steven Boyd
Name/Title:
Steven Boyd - Managing Member
Date:
05/15/2026
Steven Boyd
Signature:
/s/ Steven Boyd
Name/Title:
Steven Boyd
Date:
05/15/2026
Exhibit Information
JOINT FILING STATEMENT
PURSUANT TO RULE 13d-1(k)
The undersigned acknowledge and agree that the foregoing statement on Schedule 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.
Dated: May 15, 2026
Armistice Capital, LLC
By: /s/ Steven Boyd
Steven Boyd - Managing Member
Steven Boyd
By: /s/ Steven Boyd
